Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2019
Contact PI Name:
Mark P. Mattson
Contact PI Affiliation:
Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Co-Authors:
Peisu Zhang, Yuki Kishimoto, Ioannis Grammatikakis, Kamalvishnu Gottimukkala, Roy G. Cutler, Shiliang Zhang, Kotb Abdelmohsen, Vilhelm A. Bohr, Jyoti Misra Sen, Myriam Gorospe
Primary Reference (PubMED ID):
Funding Source:
Intramural Research Program of the National Institute on Aging
National Institute on Aging (NIA)
Study Goal and Principal Findings:

Neuritic plaques, a pathological hallmark in Alzheimer’s disease (AD) brains, comprise extracellular aggregates of amyloidbeta (Aβ) peptide and degenerating neurites that accumulate autolysosomes. We found that, in the brains of patients with AD and in AD mouse models, Aβ plaque-associated Olig2- and NG2-expressing oligodendrocyte progenitor cells (OPCs), but not astrocytes, microglia, or oligodendrocytes, exhibit a senescence-like phenotype characterized by the upregulation of p21/CDKN1A, p16/INK4/CDKN2A proteins, and senescence-associated β-galactosidase activity. Molecular interrogation of the Aβ plaque environment revealed elevated levels of transcripts encoding proteins involved in OPC function, replicative senescence, and inflammation. Direct exposure of cultured OPCs to aggregating Aβ triggered cell senescence. Senolytic treatment of AD mice selectively removed senescent cells from the plaque environment, reduced neuroinflammation, lessened Aβ load, and ameliorated cognitive deficits. Our findings suggest a role for Aβ-induced OPC cell senescence in neuroinflammation and cognitive deficits in AD, and a potential therapeutic benefit of senolytic treatments.

Bibliographic Notes:
Peisu Zhang (Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Baltimore, Maryland, USA) and Mark P. Mattson (Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA) are corresponding authors on this paper.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Dasatinib
Therapeutic Target:
Non-Receptor Tyrosine Kinase
Therapy Type:
Natural Product
Therapeutic Agent:
Quercetin
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
C57B6

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Y Maze
Histopathology
beta Amyloid Load
beta Amyloid Deposits
Biochemical
p16/Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) mRNA
Amyloid Precursor Protein (APP)
Amyloid Precursor Protein (APP) mRNA
Microtubule Associated Protein Tau (MAPT) mRNA
Presenilin 1 (PS1) mRNA
Notch 1 mRNA
beta-Site Amyloid Precursor Protein Cleaving Enzyme 2 (BACE2) mRNA
Chondroitin Sulfate Proteoglycan 4 (CSPG4) mRNA
Oligodendrocyte Transcription Factor 1 (Olig1) mRNA
Oligodendrocyte Transcription Factor 2 (Olig2) mRNA
Platelet-Derived Growth Factor Receptor A (PDGFRA) mRNA
Myelin Basic Protein mRNA
p21/Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) mRNA
p57/Cyclin-Dependent Kinase Inhibitor 1C (CDKN1C) mRNA
Transforming Growth Factor beta 1 (TGFB1) mRNA
Interleukin 1 beta (IL-1 beta) mRNA
Tumor Necrosis Factor Receptor 1 (TNFR1) mRNA
Senescence-Associated beta-Galactosidase (SA-beta Gal) Activity
Cleaved Caspase 3
Immunochemistry
Immature Oligodendrocytes
Brain-beta Amyloid Peptide 40
Brain-beta Amyloid Peptide 42
p21/Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A)
p16/Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A)
Senescence-Associated beta Galactosidase (SA-beta-Gal)
Lysosomal Associated Membrane Protein 1 (LAMP1)
Glial Fibrillary Acidic Protein (GFAP)
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
2',3'-cyclic-nucleotide-3'-phosphodiesterase (CNP)
Green Fluorescent Protein (GFP)
Interleukin 6 (IL-6)
Microscopy
Laser Capture Microdissection (LCM)
Electron Microscopy
Aggregated beta Amyloid Peptide
Oligodendrocyte Transcription Factor 2 (Olig2)
Spectroscopy
Mass Spectrometry
Cell Biology
FACS Analysis
Flow Cytometry
Apoptosis

Source URL: http://alzped.nia.nih.gov/senolytic-therapy-alleviates